Programmable Medicine

Programmable Medicine is a clinical-stage biotechnology company developing a new class of precision nanomedicines based on its proprietary hydroxyl dendrimer therapeutics (HDTs) platform, exclusively licensed from Johns Hopkins University. The company's platform precisely targets activated inflammatory cells, such as macrophages and microglia, without the need for targeting ligands, thereby minimizing off-target toxicity. Programmable Medicine operates under a unique multi-entity model where individual product assets reside in dedicated C-corporations, including Ashvattha Therapeutics (ophthalmology), Ironfist Therapeutics (radio-oncology), Nanopower Medicine (autoimmune), and ENIAC Imaging (neuro-imaging). Its clinical pipeline features migaldendranib (MGB) in Phase 2 for wet AMD and diabetic macular edema, acetylcysteine zidrimer (ACZ) in Phase 2 for ALS and hyperinflammation, and Tamrada, a preclinical TAM-targeted radiopharmaceutical.